Syndax Pharmaceuticals
SNDX
SNDX
160 hedge funds and large institutions have $1.78B invested in Syndax Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
8% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $2.56M
0.59% more ownership
Funds ownership: 105.87% → 106.47% (+0.59%)
Holders
160
Holding in Top 10
11
Calls
$2.77M
Puts
$2.56M
Top Buyers
| 1 | +$91.5M | |
| 2 | +$26.2M | |
| 3 | +$23.5M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$22.1M |
| 5 |
Barclays
London,
United Kingdom
|
+$17.5M |
Top Sellers
| 1 | -$20.1M | |
| 2 | -$19M | |
| 3 | -$14.3M | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.2M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$8.83M |